论文部分内容阅读
目的观察合并有颈动脉粥样硬化的高血压病患者阿托伐他汀强化降脂后颈动脉内膜中膜厚度(CIMT)的变化。方法选择伴有不同程度的颈动脉粥样硬化的高血压病患者126例,随机分为2组。A组(强化治疗组)65例,服用阿托伐他汀40mg,每晚1次;B组(常规治疗组)61例,服用阿托伐他汀10mg,每晚1次,疗程6个月。观察治疗前后CIMT以及总胆固醇(TC)、甘油三脂(TG)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)的变化。结果阿托伐他汀40mg、10mg(P<0.05)、TC、LDL-C(P<0.05)和升高HDL-C水平(P<0.05)。结论阿托伐他汀强化降脂能更有效地降低CIMT,以及TC和LDL-C水平,并具有良好的安全性。
Objective To observe the changes of carotid intima-media thickness (CIMT) after atorvastatin with lipid-lowering in patients with carotid atherosclerosis. Methods 126 cases of hypertensive patients with different degree of carotid atherosclerosis were randomly divided into two groups. A group (intensive treatment group) 65 cases, taking atorvastatin 40mg, 1 night; B group (conventional treatment group) 61 cases, taking atorvastatin 10mg, 1 night, a course of 6 months. The changes of CIMT, total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) were observed before and after treatment. Results Atorvastatin 40mg, 10mg (P <0.05), TC, LDL-C (P <0.05) and elevated HDL-C levels (P <0.05). Conclusions Atorvastatin can decrease CIMT, TC and LDL-C levels more effectively and have better safety.